|Systematic (IUPAC) name|
|Biological half-life||1.5 hours|
|Molar mass||562.14 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon respectively.
|This pharmacology-related article is a stub. You can help ssf by expanding it.|